{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-23-006973","form_type":"8-K","ticker":null,"cik":"0000887247","company_name":"DMK PHARMACEUTICALS Corp","filed_at":"2023-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.632845+00:00","generated_at":"2026-06-14T13:48:48.820867+00:00","sec_items":["1.01","5.02","2.01","3.02","3.03","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Adamis closes merger with DMK Pharmaceuticals; Ebrahim Versi named CEO and Chair","bullets":["Merger completed May 25; DMK shareholders received 302,815 Adamis common shares and 1,941.2 Series E Preferred shares.","Ebrahim Versi appointed CEO and Chair; David Marguglio stepped down as CEO, remains president and COO.","Series E Preferred convertible at 1,000 common per share; 9.99% beneficial ownership limitation; Nasdaq issuance cap.","Board changes: Marguglio and Williams resign; Versi and Jannine Versi appointed to board.","DMK stock options assumed: 231,490 Adamis shares; Dr. Versi holds options for 102,885 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-23-006973","json":"https://secwatch.observer/filing/0001387131-23-006973.json","markdown":"https://secwatch.observer/filing/0001387131-23-006973.md","text":"https://secwatch.observer/filing/0001387131-23-006973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/admp-8k_052423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T13:48:48.820867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e09a953c7","claim":"David J. Marguglio resigned as Director at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"David J. Marguglio and Richard C. Williams resigned from the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4c44b7e8b8","claim":"Jannine Versi was appointed as Director at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"Ebrahim Versi and Jannine Versi were appointed to the Board to fill those vacancies","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5e50713c0f","claim":"Ebrahim (Eboo) Versi was appointed as Chief Executive Officer and Chair of the Board at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"Ebrahim (Eboo) Versi, M.D., Ph.D., the co-founder and chief executive officer of DMK, was appointed as the chief executive officer of the Company and as Chair of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"cc2ef81557","claim":"David J. Marguglio was appointed as President and Chief Operating Officer at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"David J. Marguglio resigned as chief executive officer of Adamis; he continues as president of Adamis and as corporate secretary and was also appointed as chief operating officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned as chief executive officer and appointed as president and chief operating officer"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"fa6b6670df","claim":"Richard C. Williams resigned as Director at DMK PHARMACEUTICALS Corp.","evidence_excerpt":"David J. Marguglio and Richard C. Williams resigned from the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"50ec3fbb1da9c31d7111b4565154cfe9e6091ee8","claim":"DMK PHARMACEUTICALS Corp: Filed Certificate of Designation for Series E Convertible Preferred Stock, designating 15,000 shares as Series E Preferred (effective 2023-05-24).","evidence_excerpt":"On May 24, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, designating 15,000 shares out of the authorized but unissued shares of its preferred stock as Series E Preferred","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-05-24"}],"fact_type":"governance_change"},{"claim_id":"1e001156b777e3371d8fe482ca94bbc5deb21a6e","claim":"DMK PHARMACEUTICALS Corp completed an acquisition involving DMK Pharmaceuticals Corporation (closed 2023-05-25).","evidence_excerpt":"On May 25, 2023, Adamis Pharmaceuticals Corporation, a Delaware corporation (“Adamis” or the “Company”), completed its merger transaction with DMK Pharmaceuticals Corporation (“DMK”)","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"DMK Pharmaceuticals Corporation"},{"label":"Closing","value":"2023-05-25"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}